4.6 Article

A New Strategy Using ALDHhigh-CD8+T Cells to Inhibit Tumorigenesis

Journal

PLOS ONE
Volume 9, Issue 8, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0103193

Keywords

-

Funding

  1. National Natural Science Foundation of China [81201773]
  2. Specialized Research Fund for the Doctoral Program of Higher Education of China [20120171120114]
  3. Science and technology project of Fujian Province [2014J01284]

Ask authors/readers for more resources

Background: Currently, many studies suggest that cancer stem cells (CSCs) are responsible for tumor initiation, tumorigenesis, metastasis and recurrence. CSCs have been identified from various human and murine tumors. The identification of CSCs allows us to develop strategies to target the CSCs. Methods and Results: In this study, we used ALDEFLUOR as a single marker to isolate the CSCs from the human lung cancer cell line H460. We then characterized the CSCs by testing their sphere formation ability and tumorigenicity. Furthermore, we used CSC lysate-pulsed dendritic cells to stimulate CD8+T cells as a treatment strategy. Our study demonstrated that ALDEFLUOR could be used as a single marker to identify CSCs from the human lung cancer cell line H460. The ALDH(high) cells could form more spheres and were more tumorigenic than the ALDH(low) cells. Further study demonstrated that ALDH(high)-CD8+T cells conferred more significant antitumor effects, resulting in the inhibition of tumor growth and prolonged survival. And the ALDH(high)-CD8+ T cells-mediated anti-tumor immunity might be due to the directly targeting against ALDH(high) cancer stem cells (CSCs). Conclusions: This study shows that ALDH(high)-CD8+ T cells mediate anti-tumor immunity by selectively targeting cancer stem cells, which result in inhibiting tumor growth and prolonging the survival of tumor-bearing mice, which provides a new strategy using ALDH(high)-CD8+ T cells to treat tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available